Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

Thomas  Powles

Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen

Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen

Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche

Laurence  Albiges

Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)

Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer

Katriina Johanna  Jalkanen

Employment - Terveystalo (I)

Stock and Other Ownership Interests  - Faron Pharmaceuticals

Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer; Roche

Research Funding - Bayer; Lilly; Novartis; Roche

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche

Guillermo  De Velasco

No Relationships to Disclose

Mauricio  Burotto

Consulting or Advisory Role - AstraZeneca; BMS; MSD Oncology; Novartis; Roche/Genentech

Speakers' Bureau - AstraZeneca; BMS; MSD Oncology; Roche/Genentech

Pooja  Ghatalia

Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)

Cristina  Suárez

Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)

Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech

Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche

Elaine T.  Lam

Consulting or Advisory Role - Calithera Biosciences

Research Funding - Advaxis (Inst); Amgen (Inst); Argos Therapeutics (Inst); Arrowhead Pharmaceuticals (Inst); Astellas Pharma (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche/Genentech (Inst)

Roberto  Iacovelli

Honoraria - Astellas Pharma; IPSEN; MSD; Pfizer

Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Eisai; Janssen; Merck; MSD; Novartis; Pfizer; Sanofi

Speakers' Bureau - Ipsen; Janssen; MSD; Pfizer; Sanofi

Research Funding - Bristol-Myers Squibb/Celgene (Inst); Pfizer (Inst)

Travel, Accommodations, Expenses - Ipsen; Janssen; MSD; Pfizer

Mahmut  Gumus

Honoraria - GlaxoSmithKline (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst)

Consulting or Advisory Role - Amgen (Inst); Gen (Inst); Gilead Sciences (Inst); Lilly (Inst); Novartis (Inst); Roche; Takeda (Inst)

Speakers' Bureau - Amgen (Inst); MSD Oncology (Inst); Novartis (Inst); Polipharma (Inst); Roche (Inst)

Research Funding - Amgen (Inst); Pfizer (Inst); Takeda (Inst)

Travel, Accommodations, Expenses - Pfizer

Elena  Verzoni

Consulting or Advisory Role - Janssen Oncology; MSD/AstraZeneca; Pfizer

Speakers' Bureau - Ipsen; Janssen Oncology; MSD Oncology; Novartis

Christian K.  Kollmannsberger

Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Merck KGaA; Pfizer; Seagen

Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Ipsen; Janssen; Merck; Merck KGaA; Pfizer; Seagen

Travel, Accommodations, Expenses - AAA Canada; Ipsen; Janssen Oncology; Pfizer

Walter Michael  Stadler

Leadership - EMA Wellness

Stock and Other Ownership Interests  - Fortress Biotech

Consulting or Advisory Role - AstraZeneca; Bayer; Calico; CVS Caremark; Merck; Pfizer; Treadwell Therapeutics

Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Seagen (I); Tesaro (Inst); X4 Pharma (Inst); Xencor (Inst)

Expert Testimony - Apotex; Sandoz

Other Relationship - American Cancer Society; UpToDate

Balaji  Venugopal

Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck; MSD Oncology; Pfizer

Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer/EMD Serono

Speakers' Bureau - Eisai; Ipsen; Janssen Oncology; MSD Oncology; Pfizer

Research Funding - Calithera Biosciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer/EMD Serono (Inst)

Travel, Accommodations, Expenses - EUSA Pharma; Ipsen; Merck Serono

Reshma  Shinde

Employment - Merck

Stock and Other Ownership Interests  - Merck

Todd L.  Saretsky

Employment - Merck

Stock and Other Ownership Interests  - Merck

Li  He

Employment - Merck

Stock and Other Ownership Interests  - Merck

Donna  Vickery

Employment - Merck

Stock and Other Ownership Interests  - Merck

Toni K.  Choueiri

Stock and Other Ownership Interests  - Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics

Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate

Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate

Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)

Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)

Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel

Brian I.  Rini

Leadership - MashupMD; MJH Life Sciences

Stock and Other Ownership Interests  - PTC Therapeutics

Consulting or Advisory Role - Alkermes; Aravive; Arrowhead Pharmaceuticals; Athenex; AVEO; Bristol-Myers Squibb; Corvus Pharmaceuticals; Debiopharm Group; Eisai; EUSA Pharma; Genentech; HiberCell; Merck; NiKang Therapeutics; Pfizer; Surface Oncology

Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arrowhead Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Dracen (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Pionyr (Inst); Point Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Stata (Inst); Surface Oncology (Inst); Vasgene Therapeutics (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Pfizer